ipilimumab placebo

DRUG2 trials

Sponsors

Bristol-Myers Squibb

Conditions

Carcinoma, Renal CellRenal Cell Carcinoma

Phase 3

A Study Comparing Nivolumab, Nivolumab in Combination With Ipilimumab and Placebo in Participants With Localized Kidney Cancer Who Underwent Surgery to Remove Part of a Kidney

CompletedNCT03138512

Bristol-Myers SquibbCarcinoma, Renal Cell

Start: 2017-07-07End: 2024-02-01Updated: 2024-12-18

A Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer

Active, not recruitingNCT03873402

Bristol-Myers SquibbRenal Cell Carcinoma

Start: 2019-06-21End: 2027-03-11Updated: 2026-01-21

Related Papers

Adjuvant nivolumab monotherapy vs placebo for localized renal cell carcinoma at high risk of relapse after nephrectomy: Results from Part B of the randomized, phase 3 CheckMate 914 trial.

Journal of Clinical Oncology2024-01-2913 citations

Summary of Research: Adjuvant Nivolumab Plus Ipilimumab Versus Placebo for Localized Renal Cell Carcinoma After Nephrectomy (CheckMate 914): A Double-Blind, Randomized, Phase 3 Trial.

2023-09-023 citations

Adjuvant nivolumab plus ipilimumab vs placebo for patients with localized renal cell carcinoma at high risk of relapse after nephrectomy: Subgroup analyses from the phase 3 CheckMate 914 (part A) trial.

Journal of Clinical Oncology2023-06-019 citations

Update on combined immunotherapy for the treatment of advanced renal cell carcinoma.

2023-04-1627 citations

Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial.

2023-02-09118 citations

Referral and adjuvant treatment patterns after nephrectomy in high‐risk locoregional renal cell carcinoma

Cancer Medicine2021-11-093 citations

Perioperative therapy in renal cancer in the era of immune checkpoint inhibitor therapy.

2021-05-0118 citations

The role of nephrectomy in metastatic renal cell carcinoma in the immuno‐oncology era

British Journal of Urology2021-04-0910 citations

Prevalence, Disease-free, and Overall Survival of Contemporary Patients With Renal Cell Carcinoma Eligible for Adjuvant Checkpoint Inhibitor Trials.

2021-01-0735 citations

A phase III, randomized, placebo-controlled trial of nivolumab or nivolumab plus ipilimumab in patients with localized renal cell carcinoma at high-risk of relapse after radical or partial nephrectomy (CheckMate 914).

Journal of Clinical Oncology2020-05-2023 citations

Adjuvante Studie beim Nierenzellkarzinom mit hohem Rezidiv-Risiko nach Nephrektomie:

Aktuelle Urologie2020-02-01

Prevalence, disease-free (DFS) and overall (OS) survival of contemporary high-risk renal cell carcinoma (RCC) patients eligible for adjuvant checkpoint inhibitor trials: A RECUR database analysis.

Journal of Clinical Oncology2019-03-01

A phase III, randomized, placebo-controlled trial of adjuvant nivolumab plus ipilimumab in patients (pts) with localized renal cell carcinoma (RCC) who are at high risk of relapse after radical or partial nephrectomy (CheckMate 914)

Annals of Oncology2018-10-016 citations